DENVER, CO--(Marketwire - Feb 19, 2013) - ViroCyt, LLC, a life sciences company providing breakthrough analytical technologies, today announced the appointment of Jack T. Ball, Jr. to its Board. Mr. Ball previously served as Chief Commercial Officer at Accuri Cytometers, Inc., where he was responsible for worldwide sales, marketing and business development of flow cytometers. During this time, he grew both domestic and international sales, resulting in the acquisition of the company by Becton Dickinson in 2011 for $205M. Prior to his successful tenure at Accuri, Mr. Ball held senior management roles focusing on the commercialization of innovative products at Amnis, Molecular Probes, Orchid Biosciences, Amersham Pharmacia and Pharmacia Biotech.
Robert Kline, President and CEO of ViroCyt, stated, "We are all very pleased that Jack Ball has agreed to join our Board. Jack has a proven track record of implementing successful sales and marketing strategies in the life sciences field. He will be a great asset as a Board Member and advisor to ViroCyt." ViroCyt's lead product is the Virus Counter, a revolutionary system that allows users to rapidly quantify viruses that are utilized to create vaccines, express proteins or develop antiviral drugs.
"I am excited to join the Board of ViroCyt as it ramps up commercial operations to expand the sales of the Virus Counter, an exciting new product for the vaccine industry. ViroCyt will have a major impact on the viral vaccine industry with its innovative new products," said Mr. Ball. He is currently the President of Tyball Associates, Director and Vice President of the Association of Commercial Professionals - Life Sciences, Faculty at the Ross School of Business, University of Michigan and Mentor-in-Residence at the University of Michigan's Technology Transfer Office. In addition, Mr. Ball is a member of the Board of Directors of 3D Biomatrix, IntelliCyt, RealBio Technology, Swift Biosciences and SwitchGear Genomics. He received a Bachelor of Science degree in botany from the University of Georgia.
According to Dan Mitchell, Managing Director at Sequel Venture Partners and a member of the ViroCyt Board, "Jack will be a great addition. His experience is directly relevant to our task at Virocyt, which is to rapidly expand adoption of a game-changing life science instrument."
About ViroCyt, LLC
ViroCyt, LLC was formed in 2012 to focus on the commercialization of novel technologies that enable rapid quantification of viruses, such as the Virus Counter 2100. The Company's mission is to provide the tools that deliver meaningful improvements to critical biotechnology processes such as vaccine manufacturing, protein expression, antiviral development and other settings where viruses play a significant role. To learn more about ViroCyt, go to http://www.virocyt.com.